MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24

Arsenic trioxide has shown remarkable biological activity against bladder cancer in some clinical studies. However, the mechanism of its action is unknown. Our aim was to find the relationship between miRNAs and arsenic trioxide treatment by using T24 human bladder carcinoma cells. By performing microRNA microarray and quantitative real-time PCR after ATO treatment, we found that expression levels of several miRNAs, in particular, miRNA-19a, were significantly decreased in T24 cell line. Furthermore, cell proliferation assay, flow cytometry analysis, prediction of miRNA targets, Western blot analysis, and luciferase reporter assay were performed to determine the role of mir-19a in affecting the biological behaviors of T24 cells. Several miRNAs were up-regulated or down-regulated in T24 cells treated with arsenic trioxide compared to their controls. If only changes above two folds were considered, two miRNAs were identified, miRNA-19a was down-regulated, while miRNA-222* was up-regulated. Among them, knockdown of miRNA-19a by anti-miRNA-19a transfection showed a positive therapeutic effect in bladder cancer cells by inhibiting cell growth and inducing cell apoptosis targeting PTEN through the PTEN/Akt pathway. Besides this, a synergy effect was detected between knockdown of miRNA-19a and arsenic trioxide. Arsenic trioxide altered miRNA expression profile in T24 cells. It seems miRNA-19a plays a critical role in the mechanism of arsenic trioxide treatment in bladder cancer. The synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose.

[1]  K. Alimoghaddam,et al.  The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  L. Tang,et al.  Different Pathways Are Involved in Arsenic-Trioxide-Induced Cell Proliferation and Growth Inhibition in Human Keratinocytes , 2009, Skin Pharmacology and Physiology.

[3]  J. Karlsson,et al.  Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax , 2007, Oncogene.

[4]  J. Lovén,et al.  MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma , 2010, Proceedings of the National Academy of Sciences.

[5]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Zhong,et al.  MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. , 2010, Chemico-biological interactions.

[7]  W. Park,et al.  The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels. , 2009, Anticancer research.

[8]  Stefanie Dimmeler,et al.  Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. , 2010, Blood.

[9]  P. Platzer,et al.  Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. , 2008, American journal of human genetics.

[10]  Youli Zu,et al.  Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. , 2010, Leukemia research.

[11]  F. Lu,et al.  Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide , 2008, BMC Cancer.

[12]  Yunqing Li,et al.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. , 2009, Cancer research.

[13]  Hong-yan Chen,et al.  Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. , 2009, Oncology reports.

[14]  C. Kuo,et al.  miR-17-92 angiogenesis micromanagement. , 2010, Blood.

[15]  W. Park,et al.  Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. , 2009, International journal of molecular medicine.

[16]  Carlo M Croce,et al.  Apoptomirs: small molecules have gained the license to kill. , 2010, Endocrine-related cancer.

[17]  Fazlul H. Sarkar,et al.  Regulation of microRNAs by Natural Agents: An Emerging Field in Chemoprevention and Chemotherapy Research , 2010, Pharmaceutical Research.

[18]  C. Perou,et al.  A custom microarray platform for analysis of microRNA gene expression , 2004, Nature Methods.

[19]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[20]  Y. Akao,et al.  Role of anti-oncomirs miR-143 and -145 in human colorectal tumors , 2010, Cancer Gene Therapy.

[21]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[22]  E. Estey,et al.  Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.

[23]  A. Murgo.  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. , 2001, The oncologist.

[24]  Xueying Sun,et al.  Protein Kinase C Is Involved in Arsenic Trioxide-Induced Apoptosis and Inhibition of Proliferation in Human Bladder Cancer Cells , 2009, Urologia Internationalis.

[25]  Yanjie Lu,et al.  Arsenic trioxide induces the apoptosis in bone marrow mesenchymal stem cells by intracellular calcium signal and caspase-3 pathways. , 2010, Toxicology letters.

[26]  D. Friedland,et al.  Cholesteatoma Growth and Proliferation: Posttranscriptional Regulation by MicroRNA-21 , 2009, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[27]  Lei Han,et al.  MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol , 2010, BMC Cancer.

[28]  Xi Chen,et al.  The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. , 2009, Oncology reports.

[29]  W. Miller,et al.  Arsenic trioxide decreases AKT protein in a caspase-dependent manner , 2008, Molecular Cancer Therapeutics.

[30]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[31]  X. Li,et al.  Augmentation by Carnosic Acid of Apoptosis in Human Leukaemia Cells Induced by Arsenic Trioxide via Upregulation of the Tumour Suppressor PTEN , 2008, The Journal of international medical research.